HK1032012A1 - Oral liquid solution comprising the antidepressant mirtazapine - Google Patents

Oral liquid solution comprising the antidepressant mirtazapine

Info

Publication number
HK1032012A1
HK1032012A1 HK01102818A HK01102818A HK1032012A1 HK 1032012 A1 HK1032012 A1 HK 1032012A1 HK 01102818 A HK01102818 A HK 01102818A HK 01102818 A HK01102818 A HK 01102818A HK 1032012 A1 HK1032012 A1 HK 1032012A1
Authority
HK
Hong Kong
Prior art keywords
oral liquid
liquid solution
mirtazapine
antidepressant mirtazapine
antidepressant
Prior art date
Application number
HK01102818A
Other languages
English (en)
Inventor
Arnold Titus Philip Skrabanja
Roger Edward Tully
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of HK1032012A1 publication Critical patent/HK1032012A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
HK01102818A 1998-04-02 2001-04-20 Oral liquid solution comprising the antidepressant mirtazapine HK1032012A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98201037 1998-04-02
PCT/EP1999/002277 WO1999051237A1 (en) 1998-04-02 1999-03-29 Oral liquid antidepressant solution

Publications (1)

Publication Number Publication Date
HK1032012A1 true HK1032012A1 (en) 2001-07-06

Family

ID=8233550

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01102818A HK1032012A1 (en) 1998-04-02 2001-04-20 Oral liquid solution comprising the antidepressant mirtazapine

Country Status (12)

Country Link
US (2) US6040301A (pt)
EP (1) EP1067934B1 (pt)
AT (1) ATE254918T1 (pt)
AU (1) AU747975B2 (pt)
BR (1) BR9909357A (pt)
CA (1) CA2326356C (pt)
DE (1) DE69913116T2 (pt)
DK (1) DK1067934T3 (pt)
ES (1) ES2212550T3 (pt)
HK (1) HK1032012A1 (pt)
PT (1) PT1067934E (pt)
WO (1) WO1999051237A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US20040156894A1 (en) * 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
AU2005285040A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
AU2005304751A1 (en) * 2004-11-08 2006-05-18 Shire Llc Synergistic effects of combined administration of mirtazapine and a stimulant compound
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
RU2577686C2 (ru) 2010-05-05 2016-03-20 ЭНЕР-Джи-РОУТОРС, ИНК. Устройство передачи гидравлической энергии
US8714951B2 (en) * 2011-08-05 2014-05-06 Ener-G-Rotors, Inc. Fluid energy transfer device
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
DK0431663T3 (da) * 1989-12-06 1994-03-07 Akzo Nobel Nv Stabiliserende opløsninger af psykotrope midler
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5238699A (en) * 1991-11-27 1993-08-24 Kraft General Foods, Inc. Ready-to-eat, low/no-fat puddings and process

Also Published As

Publication number Publication date
DE69913116D1 (de) 2004-01-08
US6114324A (en) 2000-09-05
PT1067934E (pt) 2004-03-31
ATE254918T1 (de) 2003-12-15
DK1067934T3 (da) 2004-03-29
DE69913116T2 (de) 2004-06-03
EP1067934B1 (en) 2003-11-26
WO1999051237A1 (en) 1999-10-14
US6040301A (en) 2000-03-21
AU3604899A (en) 1999-10-25
CA2326356A1 (en) 1999-10-14
CA2326356C (en) 2008-06-03
BR9909357A (pt) 2000-12-12
AU747975B2 (en) 2002-05-30
ES2212550T3 (es) 2004-07-16
EP1067934A1 (en) 2001-01-17

Similar Documents

Publication Publication Date Title
HK1032012A1 (en) Oral liquid solution comprising the antidepressant mirtazapine
YU84703A (sh) Oralni rastvor aripiprazola
SG49049A1 (en) 5-(-2-Imidazolinylamino) benzimidazole derivatives their preparation and their use as alpha-2 adrenoceptor agonists
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
BR9917007A (pt) Moduladores de ccr5
AP2000001860A0 (en) Hypolipidemic benzothiazepine compounds.
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
WO2000002542A3 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
ATE249205T1 (de) Wässrige suspension zur nasalen verabreichung von loteprednol
HRP20010969B1 (en) Novel piperazinylalkylthiopyrimidine derivatives,
PL350917A1 (en) C16 unsaturated fp-selective prostaglandins analogs
ES2108595A1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
BR0104358A (pt) Formulações de taxana tendo solubilidade aperfeiçoada
MXPA03008837A (es) Una composicion farmaceutica estable de pravastatina.
AU6220300A (en) Benzofurylpiperazine serotonin agonists
BR9812982A (pt) Agente anti-reumático
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
MY139455A (en) Pharmaceutical composition comprising 5-methyl-2-2'(chloro-6'-fluoroanilino) phenylacetic acid
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PT1283042E (pt) Preparação líquida aquosa de pranoprofeno
WO2002070069A3 (fr) Utilisation d'un ou plusieurs shogaol(s) en tant qu'aphrodisiaque
HUT75939A (en) Intranasal composition containing active ingredient having antimigraine effect and chitosan

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090329